How big is the GLP-1 pipeline, and who is building it?
Active GLP-1 programs, each counted once at its highest phase, as of August 2026. Origin is the developer's headquarters.
Who earns the GLP-1 dollars, and by which route?
Disclosed brand net sales for Novo Nordisk and Eli Lilly from company reports. Novo figures are converted from Danish kroner at the period-average rate. The 2026 run-rate doubles first-half sales and reads as a conservative floor.
Novo Nordisk retired the Rybelsus brand for Ozempic Pill in May 2026.
Where are GLP-1s going beyond obesity and type 2 diabetes?
Active GLP-1 and incretin programs by indication outside obesity and type 2 diabetes, grouped into Sleuth clusters and counted by phase. A program pursuing several indications counts in each. Counts are approximate, as in the report. Click a cluster to see its indications.
Who is buying GLP-1 assets, and what are they paying?
GLP-1 and key-mechanism business development deals (licensing, collaboration and acquisition), 2021 through August 2026. Values are as disclosed, so totals are a floor. Click a year to list its deals.
How much weight loss is now the bar?
Best demonstrated obesity weight loss for leading incretin assets: the mean percent body-weight change at the highest studied dose, from pivotal readouts through August 2026. Timepoints differ by asset, so cross-trial comparison is our read, not head to head (except REDEFINE-4). Click a dot for the trial.
What reads out between August 2026 and the end of 2027?
Forward GLP-1 and incretin catalysts, dated by expected trial primary completion or expected regulatory decision. A ring marks a hard-outcome readout. Click a catalyst for the trial.
Which GLP-1 combinations have actually matured?
Active programs grouped by target combination into mechanism families, by stage. Beside it, a separate set of drug-plus-drug co-administration regimens; the two sets are counted apart. Click a family or an approach to see what is inside.
Who is tackling muscle loss, and do the combinations work?
Muscle-preservation positioning scored per program from public materials, layered with Phase 2 body-composition readouts from the leading muscle-preserving combinations.
Can oral GLP-1s scale against the injectables?
Route of administration across active programs with a stated route, the late-stage subset, and the split of oral programs by molecule type.
How many patients stay on GLP-1s, and why do they stop?
Discontinuation across the real-world, claims and trial studies in the report, most measured at six months, colored by each study's top reported reason. Beside it, the share of discontinuations by driver. Hover a study for its details.
Why do GLP-1 programs fail, and is it different for the incumbents?
37 discontinued or deprioritized GLP-1 and metabolic programs, sorted into six failure modes and split by incumbent (Novo, Lilly) versus entrant. Click a failure mode to list its programs.
How does China feed the West's next GLP-1s?
The China fast-follower chain end to end: the Western catalysts, the copy wave, the license-backs and the capital behind them, 2018 to 2026. Click a step to see what sits behind it.
What do we expect next?
Explore the Data Behind the Report
The Excel behind this report (Deals, Weight Loss Benchmarks, Discontinued Programs, and China Fast-Followers) is free for Sleuth Intelligence Community members. Not a member yet? Join the community.